Opinion

Cancer research
#AACR #AACR 2025 #Cancer research #Opinion

Expert reflections from AACR 2025

DDW’s Megan Thomas hears from industry experts Daniel Veres, Turbine’s Chief Scientific Officer & Co-Founder, as well as Ryan Jacobs, Business Development Manager at Astoriom, about AACR 2025. MT: What do you consider to be the key trends in cancer research? Daniel Veres: Key trends in cancer research include a… Read More

#Cancer Research #Exclusive Content #Opinion

Advanced therapies
#Advanced Therapies #Cell and gene therapy #Events #Opinion

Hot topics, news and discussions at Advanced Therapies Week 2025

Advanced Therapies Week (ATW) 2025 took place Dallas, US, from 20-23 January 2025. DDW’s Megan Thomas hears from industry experts in attendance and reports on news from the event.  Patient perspective Michalle Adkins, Director of Life Sciences Strategy and Direction at Emerson USA, said: “One of the most exciting things… Read More

#Business & Investment #Exclusive Content #Opinion

World Health Organization
#Big pharma #Drug development #Opinion #Politics #World Health Organization

How will a Trump withdrawal from the WHO impact drug development?

In one of his first acts as President, Donald Trump signed an executive order to withdraw the US from the World Health Organization (WHO). DDW’s Megan Thomas spoke with three industry leaders to understand the impact this will have on the drug development sector. Cell and gene therapy According… Read More

#Business & Investment #Exclusive Content #Opinion #Regulatory

#Biotechnology #Cancer research #Clinical trials #Drug development #Drug discovery #Drug targets #Opinion #Podcasts

The DDW Podcast: 2024 in review

As 2024 draws to a close, DDW’s Multimedia Editor and podcast host Megan Thomas rounds up all the free editorial episodes of the DDW podcast that were released. You can find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. DDW Highlights Innovative. Evolving. Developing. Busy. These… Read More

#News

European Commission
#Biosimilars #Comment #European Commission #Opinion #Pharma #Regulatory

European Commission vs Big Pharma, or profit vs access?  

On January 31 2023, an internally circulated version of the European Commission’s overhaul of the EU’s pharma legislation was leaked, and published by Politico1. Politico published a summary of the key propositions outlined in the draft2, and DDW’s Multimedia Editor Megan Thomas investigates their intention,… Read More

#Exclusive Content #Opinion #Regulatory

#Clinical trials #Drug development #Opinion #Patient centricity #Public health

What can patients do to give input into clinical trial design? 

Business and profitability remain unquestionably important in the drug discovery community. However, the industry’s overarching goal of public health and the betterment of society have never been more apparent than in the aftermath of the pandemic and when observing the heights scientists reached through determination and collaboration in the… Read More

#Exclusive Content #Opinion